Cytarabine

Catalog No.S1648

Cytarabine Chemical Structure

Molecular Weight(MW): 243.22

Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.

Size Price Stock Quantity  
USD 97 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 12 Publications

3 Customer Reviews

  • Viability and CI vs Fa after 24-h exposure to cytarabine alone or in combination with ABT-199 in Riva, U2932 and VavP-Bcl2/c-MYC murine tumor cells. Viability shown at 500 nM (500 ng/ml for cytarabine; quadruplicates±s.e.m.).

    Leukemia, 2015, 29(8): 1702–1712. Cytarabine purchased from Selleck.

    Cell cycle was analyzed using propidium iodide (PI) staining and flow cytometry. The plots show PI staining at the x-axis and cell counts at the y-axis. The graphs were prepared using ModFit LT™ software (Verity Software House). Nd: not detected, Ara-c:Cytarabine

    J Exp Clin Cancer Res, 2017, 36(1):22. Cytarabine purchased from Selleck.

  • Flow cytometry analysis for cell surface expression of CD11b shows time- and dose-dependent upregulation of the marker CD11b in MLL-rearranged leukemia cells treated with EPZ-5676 and Cytarabine(Ara-C) as single agents and in combination.

    J Pharmacol Exp Ther, 2014, 350(3): 646-56. Cytarabine purchased from Selleck.

Purity & Quality Control

Choose Selective DNA/RNA Synthesis Inhibitors

Biological Activity

Description Cytarabine is an antimetabolic agent and DNA synthesis inhibitor with IC50 of 16 nM in wild-type CCRF-CEM cells.
Features The 1st of a series of cancer drugs that alters the sugar component of nucleosides.
Targets
DNA synthesis [1]
(CCRF-CEM cells)
16 nM
In vitro

Cytarabine (AraC) is phosphorylated into a triphosphate form (Ara-CTP) involving deoxycytidine kinase (dCK), which competes with dCTP for incorporation into DNA, and then blocks DNA synthesis by inhibiting the function of DNA and RNA polymerases. Cytarabine displays a higher growth inhibitory activity towards wild-type CCRF-CEM cells compared to other acute myelogenous leukemia (AML) cells with IC50 of 16 nM. [1] Increasing concentrations of Cytarabine (IC50 of 0.69 μM) results in decreased metabolic activity of sensitive rat leukemic cell line RO/1, and the cell toxity can be highly enhanced by transfection with human wt dCK (IC50 of 0.037 μM) but not the inactive, alternatively spliced dCK forms. [2] Cytarabine apparently induces apoptosis of rat sympathetic neurons at 10 μM, of which 100 μM shows the highest toxicity and kills over 80% of the neurons by 84 hours, involving the release of mitochondrial cytochrome-c and the activation of caspase-3, and the toxicity can be attenuated by p53 knockdown and delayed by bax deletion. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
mouse L1210 cells M3jafWN6fG:2b4jpZ:Kh[XO|YYm= M{fmNFMh\GG7cx?= M{nRXWN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGSnb4j5cpVkdGWxc3nk[UBidmGub3f1[U1{\W6|aYTpeoUhdW:3c3WgUFEzOTBiY3XscJMh[W[2ZYKgN{Bl[Xm|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlQhdk1w M{\WclE6Pjd2OUCz
human CCRF-CEM cells NEfVT3JEgXSxdH;4bYPDqGG|c3H5 NXnjZ2p{OyCmYYnz MkHaR5l1d3SxeHnjbZR6KGGpYXnud5Qh\GWxeInueYNt\W:|aXTlJIFv[WyxZ4XlMZNmdnOrdHn2[UBpfW2jbjDDR3JHNUOHTTDj[YxteyCjZoTldkA{KGSjeYOgZpkhVVSWIHHzd4F6NCCLQ{WwQVEhdk1w MUCxPVY4PDlyMx?=
human MCF7 cells NUTFXYVNS3m2b4TvfIlkyqCjc4PhfS=> NVTqdJN{OyCmYYnz NXPOXpY4S3m2b4TvfIlkcXS7IHHnZYlve3RiZHXvfJlvfWOuZX;zbYRmKGGwYXzv[5VmNXOnboPpeIl3\SCqdX3hckBOS0Z5IHPlcIx{KGGodHXyJFMh\GG7czDifUBOXFRiYYPzZZktKEmFNUC9OEBvVS5? MYOxPVY4PDlyMx?=
CCRF-CEM cell line MnjnSpVv[3Srb36gZZN{[Xl? NUXxdmRZUW6qaXLpeEB1cGVicnXwcIlk[XSrb36gc4YhS0OURj3DSW0h[2WubDDsbY5mKGmwII\peJJwNCCHREWwQVUhdk1w NIHnRXcyQTl3OEm0
human P12-ICHIKAWA cell MonOS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVv6XlZOUW6qaXLpeIlwdiCxZjDoeY1idiCSMUKtTWNJUUuDV1GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlU1KG6PLh?= MorWV2FPT0WU
human CCRF-CEM cells NX;kV|lCS3m2b4TvfIlkyqCjc4PhfS=> NGHnc4w1QCCq NE\Pd|ZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUUBk\WyuczDh[pRmeiB2ODDodpMh[nliY3XscEB1cXSncj3icJVmKGG|c3H5MEBGSzVyPUWuOlEhdk1w NHvYOIsyQTd2M{i1PC=>
CCRF-CEM cell lines M4PYW2Z2dmO2aX;uJIF{e2G7 MXy3NkBp NUnY[FBPS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JJJmeGyrY3H0bY9vKG:oIFPDVmYuS0WPIHPlcIwhdGmwZYOgZpkhPTBnIHHmeIVzKDd{IHjyJIlv[3WkYYTpc44tKEWGNUC9OkBvVS5? MYqxOlUzODJ2
human CCRF-CEM cells MlXpR5l1d3SxeHnjxsBie3OjeR?= MWG0PEBp NGX5cWxEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBES1KILVPFUUBk\WyuczDhd5Nme3OnZDDhd{Bk\WyuII\pZYJqdGm2eTDh[pRmeiB2ODDodpMh[nliY3XscJRqfGW{LXLseYUh[XO|YYmsJGlEPTB;NjDuUU4> NEC5fXIzOjV6Mkm5NS=>
human SF268 cells M{jwVWN6fG:2b4jpZ:Kh[XO|YYm= NFW5cGZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBUTjJ4ODDj[YxteyCkeTDNWHQh[XO|YYmsJGlEPTB;Nz62PEBvVS5? MVyxPVM1PTV6MR?=
MOLT-4 human leukemic lymphoblastoid cell lines NFzSNG9EgXSxdH;4bYPDqGG|c3H5 MkHKR5l1d3SxeHnjbZR6KGGpYXnud5QhVU:OVD20JIh2dWGwIHzleYtmdWmlIHz5cZBpd2KuYYP0c4llKGOnbHygcIlv\XNuIFnDOVA:OTBibl2u NIm0W4Q3QDJ5NUS2
human 697 cell NFv1NWlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVXYbYFXUW6qaXLpeIlwdiCxZjDoeY1idiB4OUegZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xNE43KG6PLh?= M3LFVHNCVkeHUh?=
human ES1 cell M13oWmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M{P4b2lvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKuPVchdk1w M3\xcHNCVkeHUh?=
CCRF-CEM human leukemic lymphoblastoid cell lines MlnhR5l1d3SxeHnjxsBie3OjeR?= NY\HZZJvS3m2b4TvfIlkcXS7IHHnZYlve3RiQ1PSSk1ETU1iaIXtZY4hdGW3a3XtbYMhdHmvcHjvZoxie3SxaXSgZ4VtdCCuaX7ld{whUUN3ME2yNEBvVS5? NW\IPHRnPjh{N{W0Oi=>
P388 murine cell lines M4nwfWZ2dmO2aX;uJIF{e2G7 M4X2R|czKGh? MXHUbIUh[2:vcH;1coQhf2G|IITld5Rm\CCrbjD2bZRzdyCob4KgZY51cXS3bX;yJIFkfGm4aYT5LFUxLSCrbnjpZol1cW:wIH;mJJR2dW:{IHPlcIwh\3Kxd4ToLUBi\2GrboP0JJRp\SCSM{i4JI12emmwZTDj[YxtKGyrbnXzJIFnfGW{IEeyJIhwfXK|LDDJSFUxRTJyIH7NMi=> NYq3Z5dbOzZ{NUexOC=>
L1210 murine cell lines M{nW[WZ2dmO2aX;uJIF{e2G7 NIiwO4o4OiCq NUnTWmt[XGinIHPvcZBwfW6mIIfhd{B1\XO2ZXSgbY4hfmm2cn:g[o9zKGGwdHn0eY1weiCjY4Tpeol1gSh3MDWgbY5pcWKrdHnvckBw\iC2dX3vdkBk\WyuIHfyc5d1cCliYXfhbY5{fCC2aHWgUFEzOTBibYXybY5mKGOnbHygcIlv\XNiYX\0[ZIhPzJiaH;1dpMtKEmGNUC9NlAhdk1w NHr5dlk{PjJ3N{G0
human HEL cell M2XYT2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXnJcohq[mm2aX;uJI9nKGi3bXHuJGhGVCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTJyLkWyJI5ONg>? MVLTRW5ITVJ?
human CCRF-CEM/C2 cells NYCzeXBsS3m2b4TvfIlkyqCjc4PhfS=> MV60PEBp MnPER5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2NTTi2FRV2vR|Ih[2WubIOgZYZ1\XJiNEigbJJ{KGK7IHPlcIwhfGm2ZYKtZox2\SCjc4PhfUwhTUN3ME2yNk45KG6PLh?= NYDYco1EOTl5NEO4OVg>
mouse L1210 cells M{fDU2N6fG:2b4jpZ:Kh[XO|YYm= NYPieIt1PDhiaB?= MYrDfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDMNVIyOCClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC0PEBpenNuIFnDOVA:OC5yMkSg{txONg>? MmCzNlAxODB2MUi=
human CEM cells MlHRR5l1d3SxeHnjxsBie3OjeR?= NHTBdJY1QCCq M2HTe2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGNGVSClZXzsd{Bie3Onc4Pl[EBieyCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBi\nSncjC0PEBpenNuIFnDOVA:OC5yMkSg{txONg>? MVKyNFAxODRzOB?=
human 2209-23 cells MVnQdo9tcW[ncnH0bY9vKGG|c3H5 NUC2Oot{SW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjCyNlA6NTJ|IHPlcIx{KGK7IGuzTH11cHmvaXTpcoUhcW6lb4Lwc5JifGmxbjDzZ4lvfGmubHH0bY9vKHC{b4jpcYl1gSCjc4PhfUwhUUN3ME2wMlAzQSEQvF2= MkjsNVkxPTV2OEK=
human CHP-212 cell M2O3UWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVLye49JUW6qaXLpeIlwdiCxZjDoeY1idiCFSGCtNlEzKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OzNwNEegcm0v MYHTRW5ITVJ?
human CTB-1 cell MkfTS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Ml7MTY5pcWKrdHnvckBw\iCqdX3hckBEXEJvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUO0MlMhdk1? NVXxUmZKW0GQR1XS
human A427 cell M{DXUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYfQWW5UUW6qaXLpeIlwdiCxZjDoeY1idiCDNEK3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N|QvPDlibl2u MWDTRW5ITVJ?
human MOLT-16 cell NVPqbYFCT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MVTJcohq[mm2aX;uJI9nKGi3bXHuJG1QVFRvMU[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zOk4xPyCwTT6= MVTTRW5ITVJ?
human MCF7 1K cells M1\RWGN6fG:2b4jpZ:Kh[XO|YYm= NHTH[YM{KGSjeYO= MYPDfZRwfG:6aXPpeJkh[WejaX7zeEBl\W:6eX71Z4xmd3OrZHWgZY5idG:pdXWtdoV{cXO2YX70JIh2dWGwIF3DSlchOUtiY3XscJMhd3[ncnX4dJJme3Orbnegdoljd263Y3zlc5Rq\GVicnXkeYN1[XOnIHHmeIVzKDNiZHH5d{BjgSCPVGSgZZN{[XluIFnDOVA:PDBibl2u NIPnSGEyQTZ5NEmwNy=>
human MC-IXC cell NGTKc5pIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlfZTY5pcWKrdHnvckBw\iCqdX3hckBOSy2LWFOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20NU41OSCwTT6= NXL1TG1tW0GQR1XS
human BHT-101 cell MXvHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MkOzTY5pcWKrdHnvckBw\iCqdX3hckBDUFRvMUCxJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OFEvPzZibl2= NVfifZdjW0GQR1XS
human K5 cell MojYS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MonaTY5pcWKrdHnvckBw\iCqdX3hckBMPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTR|LkKgcm0> MXzTRW5ITVJ?
parent promyelocytic leukemia cell line MnXRSpVv[3Srb36gZZN{[Xl? NX7VfXhZSW62aXPhcoNmeiCjY4Tpeol1gSC5YYOg[ZZidHWjdHXkJIZweiC2aHWgZ49ueG:3bnSgZYdicW6|dDDwZZJmdnRicILvcZlmdG:leYTpZ{Bt\XWtZX3pZUBk\WyuIHzpcoUhMEiOLU[wMWdJWFKWKz;kR2ssMSxiRVS1NF01PyCwTT6= M2HqV|MxOjd|Mkm=
human HL60 cells NHHMNWZEgXSxdH;4bYPDqGG|c3H5 NW\aWFB1S3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hUEx4MDDj[YxteyCjc4Pld5Nm\CCjczDj[YxtKH[rYXLpcIl1gSCjZoTldkA1QCCqcoOgZpkh[2WubITpeIVzNWKudXWgZZN{[XluIFnDOVA:OC5yNEmg{txONg>? MXyyNlU5Ojl7MR?=
human A549 cell NUm1XJFNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4rxbGlvcGmkaYTpc44hd2ZiaIXtZY4hSTV2OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUS5MlY3KG6P MUXTRW5ITVJ?
human NCI-H1703 cell NGjCVY9Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHUTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG3NFMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01QS56MTDuUS=> NFPXTZFUSU6JRWK=
L1210 cell lines M1nMdWZ2dmO2aX;uJIF{e2G7 NW\3NFhHS2:wY3XueJJifGmxbjDy[ZF2cXKnZDD0c{BqdmirYnn0JJJmeGyrY3H0bY9vKG:oIFyxNlExKGOnbHygcIlv\XNiYomgOVAmKGGodHXyJFczKGi{IHnuZ5Vj[XSrb36sJGVFPTB;MD6wOUDPxE1w M2DNeFE3PTJyMkS=
human K562 cells NIDmdWpEgXSxdH;4bYPDqGG|c3H5 NE\0fmZEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBMPTZ{IHPlcIx{KGK7IGPSRkBie3OjeTygTWM2OD1yLkC1JO69VQ>? NHfUfIczPDl3NkW1Oi=>
human LB2241-RCC cell MofmS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NHf6[HRKdmirYnn0bY9vKG:oIHj1cYFvKEyEMkK0NU1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13NT6zOEBvVQ>? M1XSbXNCVkeHUh?=
human MLMA cell MYjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NGLm[YtKdmirYnn0bY9vKG:oIHj1cYFvKE2OTVGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21OU42OSCwTR?= NGjU[ndUSU6JRWK=
human P30-OHK cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NYXrdYJrUW6qaXLpeIlwdiCxZjDoeY1idiCSM{CtU2hMKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PTZwNTDuUS=> NGj1[G9USU6JRWK=
RPMI-6410 human leukemic lymphoblastoid cell lines NFj6eJBEgXSxdH;4bYPDqGG|c3H5 NUDYeGU1S3m2b4TvfIlkcXS7IHHnZYlve3RiUmDNTU03PDFyIHj1cYFvKGyndXvlcYlkKGy7bYDoc4Jt[XO2b3nkJINmdGxibHnu[ZMtKEmFNUC9NE4xPiEQvF2= M2HH[FY5Ojd3NE[=
human HT-29 cells NHfXV3lRem:uaX\ldoF1cW:wIHHzd4F6 MWTBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEiWLUK5JINmdGy|IHHmeIVzKDl4IHjyd{BjgSCPVGSgZZN{[XluIFnDOVA:OC5yNk[g{txONg>? MX:yO|c5PDR7
human NCI-H510A cell NWDsVnozT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M4\2SmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVi1NVBCKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjhwMk[gcm0> M2LPNHNCVkeHUh?=
human J-RT3-T3-5 cell NH3rdpVIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MknsTY5pcWKrdHnvckBw\iCqdX3hckBLNVKWMz3UN{02KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PjhwNEKgcm0> MkjRV2FPT0WU
human VA-ES-BJ cell MljNS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVnlcY56UW6qaXLpeIlwdiCxZjDoeY1idiCYQT3FV{1DUiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTdzLk[1JI5O M2DoSHNCVkeHUh?=
human T-24 cell M1exfGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M4LwTGlvcGmkaYTpc44hd2ZiaIXtZY4hXC1{NDDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe4MlU3KG6P NYGyfHppW0GQR1XS
human NB69 cell MmHkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{LhTmlvcGmkaYTpc44hd2ZiaIXtZY4hVkJ4OTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUe5MlQ5KG6P M33ud3NCVkeHUh?=
human BALL-1 cells Mn3iS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmjPNlQhcA>? M1n4Rmdzd3e2aDDpcohq[mm2aX;uJI9nKGi3bXHuJGJCVExvMTDj[YxteyCjZoTldkAzPCCqcoOgZpkhX1OWLUGgZZN{[XluIFfJOVA:OC5yODFOwG0> MkXLNlIzPjRzN{C=
HL60 cells NILqc25Rem:uaX\ldoF1cW:wIHHzd4F6 M4rucGlvKH[rdILvJIlvcGmkaYTvdpkh[2:wY3XueJJifGmxbjDh[4FqdnO2IIDyc4xq\mW{YYTpc44hd2ZiSFy2NEBk\WyuczygTWM2OD1yLkC4JO69VQ>? NWTQTY5mOTJ6N{e1PVM>
human CTV-1 cell M4TpUmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M3nl[2lvcGmkaYTpc44hd2ZiaIXtZY4hS1SYLUGgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME24OE44PCCwTR?= NUSyPZF4W0GQR1XS
human MEL-JUSO cell NGfjRoRIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NVfLXI1tUW6qaXLpeIlwdiCxZjDoeY1idiCPRVytTnVUVyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTh3Lke2JI5O NGDNVmtUSU6JRWK=
human MOLT-4 cell M130[2dzd3e2aDDpcohq[mm2aX;uJIF{e2G7 M1LMfWlvcGmkaYTpc44hd2ZiaIXtZY4hVU:OVD20JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9PFkvPjdibl2= MYfTRW5ITVJ?
human leukemia cell line(CCRF-CEM) MkDvR5l1d3SxeHnjxsBie3OjeR?= M3n5W2lvKH[rdILvJIN6fG:2b4jpZ4l1gSCxZjDjc41xd3WwZIOge4Vz\SCmZYTldo1qdmWmIH;uJGlvcGmkaYTpc44hd2ZiaIXtZY4hdGW3a3XtbYEh[2WubDDsbY5mMEOFUl[tR2VOMSxiSVO1NF0xNjB7IN88UU4> MWO4PVE4PjR3
human SW982 cell M{XSfmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MXzJcohq[mm2aX;uJI9nKGi3bXHuJHNYQTh{IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;OUGuNlMhdk1? M4j1ZnNCVkeHUh?=
human NCI-SNU-1 cell M1\xemdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NIHlbZhKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3TUnUuOSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G778{MJGlEPTB;OU[uO|chdk1? M3fUe3NCVkeHUh?=
HeLa human cell lines M4izdWZ2dmO2aX;uJIF{e2G7 NXiyWIZzOTR2IHi= MlGxWIhmKGOxbYDveY5lKHejczD0[ZN1\WRiaX6geol1em9iZn;yJIFvfGm2dX3vdkBi[3Srdnn0fUg2OCViaX7obYJqfGmxbjDv[kB1fW2xcjDj[YxtKGe{b4f0bEkh[WejaX7zeEBJ\UyjIHj1cYFvKGOnbHygcIlv\XNiYX\0[ZIhOTR2IHjyMEBKTDVyPUCuNUDPxE1? NYG2[nhHOzZ{NUexOC=>
human H460 cells NVnRfoltTnWwY4Tpc44h[XO|YYm= M{PYTlI1KGh? M{nY[GFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFi0OlAh[2WubIOgZYZ1\XJiMkSgbJJ{KGK7IF3UWEBie3OjedMg MnTXNlAzOTF3NkS=
human HCT116 cells M4[x[mZ2dmO2aX;uJIF{e2G7 NEfYT3VCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgNlQhcHK|IHL5JG1VXCCjc4PhfUwhUUN3ME2wMlEh|ryP NV7iZ4ZsOjB{MUG1OlQ>
human GP5d cell MUHHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NWXXSYJGUW6qaXLpeIlwdiCxZjDoeY1idiCJUEXkJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVAzKG6P NFvjT|dUSU6JRWK=
human SAS cell MVTHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mki1TY5pcWKrdHnvckBw\iCqdX3hckBUSVNiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zMEeuOVchdk1? NUWwfoJPW0GQR1XS
human BFTC-905 cell  NX\xbYo2T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NGTkfXlKdmirYnn0bY9vKG:oIHj1cYFvKEKIVFOtPVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTB6LkOxJI5O NGTK[WlUSU6JRWK=
human LB1047-RCC cell MUPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnfDTY5pcWKrdHnvckBw\iCqdX3hckBNSjFyNEetVmNEKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTB6LkSyJI5O MYHTRW5ITVJ?
human BB65-RCC cell MYfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MlHVTY5pcWKrdHnvckBw\iCqdX3hckBDSjZ3LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVEyOC5zOTDuUS=> M3fiW3NCVkeHUh?=
human KE-37 cell NXS4dZNOT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NHPGWYNKdmirYnn0bY9vKG:oIHj1cYFvKEuHLUO3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVExNjh3IH7N NFmxd2VUSU6JRWK=
human NCI-H292 cell MmmwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MY\Jcohq[mm2aX;uJI9nKGi3bXHuJG5EUS2KMkmyJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVE1NjJibl2= MUXTRW5ITVJ?
human HT-1080 cell MVLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHS1OGhKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0yOTRwNEegcm0> NXLzc2JUW0GQR1XS
human HL60 cells MXLDfZRwfG:6aXRCpIF{e2G7 M{W5OFQ5KGh? MVzDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIUFYxKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDNWHQh[XO|YYmsJGlEPTB;MD6xNVgh|ryP M1vI[VE6OzJzMkO0
human CAKI-1 cell Mnf3S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{OyfWdzd3e2aDDpcohq[mm2aX;uJI9nKGGpYXnud5QhcHWvYX6gTGNVOTF4IHPlcIx{KGGodHXyJFI1KGi{czDifUBYW1RvMTDhd5NigSxiR1m1NF0xNjF{IN88US=> Ml3CNlIzPjRzN{C=
human CAKI-1 cell MYXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MYDJcohq[mm2aX;uJI9nKGi3bXHuJGNCU0lvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUGyNEBvVQ>? Mn;QV2FPT0WU
human HMV-II cell NEnF[3dIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIPwVWNKdmirYnn0bY9vKG:oIHj1cYFvKEiPVj3JTUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6 NEDPNI9USU6JRWK=
human ES8 cell MoTsS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M{e3XmlvcGmkaYTpc44hd2ZiaIXtZY4hTVN6IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUKzMlk{KG6P Ml;GV2FPT0WU
human NEC8 cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NVGxbpVmUW6qaXLpeIlwdiCxZjDoeY1idiCQRVO4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NVM1NjJzIH7N MojHV2FPT0WU
human EW-1 cell NGmyO5JIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MlLNTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MUO4MlYzKG6P NXqxR5BrW0GQR1XS
murine leukemia P388 Mk\QSpVv[3Srb36gZZN{[Xl? NXjO[JVLSW62aXPhcoNmeiCjY4Tpeol1gSClYYLybYVlKG:3dDDpckB3cXS{bzDh[4FqdnO2IH31dolv\SCuZYXr[Y1q[SCSM{i4MEBKSzVyPUCuNVQh|ryP M{HReFEyOzV4MUGw
human H-EMC-SS cell MkLtS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NV35e5RWUW6qaXLpeIlwdiCxZjDoeY1idiCKLVXNR{1UWyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTF2NT6yPEBvVQ>? MlfqV2FPT0WU
human SNU638 cells MXvDfZRwfG:6aXRCpIF{e2G7 Ml;FR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gV25WPjN6IHPlcIx{KGK7IGPSRkBie3OjeTygTWM2OD1yLkG1JO69VQ>? NWrE[2VLOjR7NU[1OVY>
human COR-L105 cell NGr0PHpIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NIn4R3hKdmirYnn0bY9vKG:oIHj1cYFvKEORUj3MNVA2KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:OTZyLkO5JI5O NWW1cW9HW0GQR1XS

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-mTOR / mTOR / p-S6K / S6K / p-AMPK / AMPK / p-AKT / AKT / p-ERK / ERK ; 

PubMed: 24714637     


REH cells were incubated for the indicated time periods with cytarabine (3.2 μM) and the levels of phosphorylated/total mTOR, p70S6K, AMPK, Akt and ERK were determined by immunoblotting. The representative blots from three independent experiments are shown.

24714637
Growth inhibition assay
Cell viability; 

PubMed: 24714637     


REH cells were incubated in the presence of different concentrations of cytarabine and cell viability was determined by acid phosphatase assay after 24 h and 48 h. The data are mean ± SD values of triplicate measurements from a representative of three independent experiments (*p<0.05 compared to untreated cells). 

24714637
In vivo Cytarabine is highly effective against acute leukaemias, which causes the characteristic G1/S blockage and synchronization, and increases the survival time for leukaemic Brown Norway rats in a weak dose-related fashion indicating that the use of higher dosages of Cytarabine does not contribute to its antileukaemic effectiveness in man. [4] Cytarabine (250 mg/kg) also causes placental growth retardation and increases placental trophoblastic cells apoptosis in the placental labyrinth zone of the pregnant Slc:Wistar rats, which increases from 3 hour after the treatment and peaks at 6 hour before returning to control levels at 48 hour, with remarkably enhanced p53 protein, p53 trancriptional target genes such as p21, cyclinG1 and fas and caspase-3 activity. [5]

Protocol

Kinase Assay:[1]
+ Expand

In Vitro Growth Inhibition Assay:

Stock solution of Cytarabine is prepared in absolute ethanol, and serial dilutions of Cytarabine are prepared. CCRF-CEM cells are suspended in RPMI medium supplemented with 10% FBS, 0.1% gentamicin, and 1% sodium pyruvate. The cells are suspended in their respective media to give 10 mL volumes of cell suspension at a final density of 3-6 × 104 cells/mL. Appropriate volumes of Cytarabine solution are transferred to the cell suspensions, and incubation is continued for 72 hours. The cells are spun down and resuspended in fresh Cytarabine -free medium, and final cell counts are determined. The data are analyzed by sigmoidal curve fitting of the cell count versus Cytarabine concentration, and the results are expressed as the IC50 (Cytarabine concentration that inhibits cell growth to 50% of the control value).
Cell Research:[2]
+ Expand
  • Cell lines: Rat leukemic cell lines RCL/0, RO/1 and K7 and human myelomonocytic leukemic U937
  • Concentrations: ~100 μM
  • Incubation Time: 24, 48 and 72 hours
  • Method: Cells are incubated in the presence of different concentrations of Cytarabine at 37 °C for 24, 48, and 72 hours. At the time of 20-, 44-, or 68-hour incubation in the presence of Cytarabine, 10 mL of cell proliferation reagent WST-1 solution is added. After 2- and 4-hour incubation with WST-1, cell metabolic activity is assessed with colorimetric changes quantified by measuring the absorbance in a spectrophotometer at 450 nm. And cell division times are calculated from eosin counting in parallel with viability assay
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: Brown Norway rat with myelocytic leukaemia
  • Formulation: Dissolved in phosphate-buffered saline (pH 7.0) just before use.
  • Dosages: 5 - 1000 mg/kg
  • Administration: Injection i.v.
    (Only for Reference)

Solubility (25°C)

In vitro Water 48 mg/mL (197.35 mM)
DMSO 1 mg/mL (4.11 mM)
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
Saline
For best results, use promptly after mixing.
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 243.22
Formula

C9H13N3O5

CAS No. 147-94-4
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04113616 Recruiting Drug: KRT-232|Drug: Cytarabine|Drug: Decitabine Acute Myeloid Leukemia (AML)|Acute Myeloid Leukemia (AML) Secondary to Myeloproliferative Neoplasms (MPN) Kartos Therapeutics Inc. September 25 2019 Phase 1|Phase 2
NCT03878927 Recruiting Drug: CPX-351|Drug: Gemtuzumab Ozogamicin Acute Myeloid Leukemia Weill Medical College of Cornell University|Jazz Pharmaceuticals|Pfizer August 23 2019 Phase 1
NCT03896269 Recruiting Drug: Liposome-encapsulated Daunorubicin-Cytarabine Blasts 10-19 Percent of Bone Marrow Nucleated Cells|Blasts More Than 5 Percent of Bone Marrow Nucleated Cells|High Risk Chronic Myelomonocytic Leukemia|Recurrent Chronic Myelomonocytic Leukemia|Recurrent High Risk Myelodysplastic Syndrome|Refractory Chronic Myelomonocytic Leukemia|Refractory High Risk Myelodysplastic Syndrome M.D. Anderson Cancer Center|National Cancer Institute (NCI) May 14 2019 Phase 1
NCT03348033 Enrolling by invitation Biological: Chronic Myeloid Leukemia + NK cell Chronic Myeloid Leukemia Hospital de Clinicas de Porto Alegre March 2019 Phase 1|Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

DNA/RNA Synthesis Signaling Pathway Map

Related DNA/RNA Synthesis Products

Tags: buy Cytarabine | Cytarabine supplier | purchase Cytarabine | Cytarabine cost | Cytarabine manufacturer | order Cytarabine | Cytarabine distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID